新诺威(300765) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥471,967,670.63, representing a decrease of 9.94% compared to ¥524,066,868.93 in the same period last year[5]. - The net profit attributable to shareholders for Q1 2025 was a loss of ¥26,901,607.29, a decline of 134.03% from a profit of ¥79,061,260.62 in Q1 2024[5]. - Total operating revenue for the current period was ¥471,967,670.63, a decrease of 9.9% compared to ¥524,066,868.93 in the previous period[22]. - The company reported a net profit of -142,361,032.21 yuan for the current period, compared to a net profit of 29,961,530.26 yuan in the previous period, indicating a significant decline[23]. - Operating profit for the current period was -126,574,064.46 yuan, while the previous period showed an operating profit of 56,155,547.90 yuan, reflecting a substantial decrease[23]. - The total comprehensive income for the current period was -142,313,442.07 yuan, compared to 29,589,098.69 yuan in the previous period[23]. - Basic and diluted earnings per share for the current period were both -0.0192 yuan, down from 0.0676 yuan in the previous period[23]. Cash Flow and Liquidity - The net cash flow from operating activities improved significantly, with a net outflow of ¥86,799,597.52, a 91.10% reduction compared to a net outflow of ¥975,365,408.34 in the previous year[12]. - Cash and cash equivalents at the end of the period reached ¥1,298,752,857.02, up 48.9% from ¥872,081,872.91 at the beginning of the period[19]. - The company reported cash and cash equivalents at the end of the period amounting to 1,298,752,857.02 yuan, a decrease from 2,686,302,001.07 yuan at the end of the previous period[26]. - The company generated cash inflow from investment activities amounting to 472,270,137.70 yuan, with a net cash flow from investment activities of 361,108,752.50 yuan[26]. - The company recorded a total operating cash inflow of 443,386,291.36 yuan, down from 576,280,891.81 yuan in the previous period[25]. - The company received 163,000,000.00 yuan from financing activities, resulting in a net cash flow from financing activities of 163,000,000.00 yuan[26]. Assets and Liabilities - The total assets at the end of Q1 2025 were ¥6,092,264,108.12, reflecting a 1.16% increase from ¥6,022,115,755.32 at the end of the previous year[5]. - Total assets increased to ¥6,092,264,108.12, compared to ¥6,022,115,755.32 at the beginning of the period, reflecting a growth of 1.2%[20]. - Total liabilities rose to ¥1,734,625,266.13, an increase of 13.7% from ¥1,526,185,458.97 in the previous period[20]. - The company's total equity decreased to ¥4,357,638,841.99 from ¥4,495,930,296.35, a decline of 3.1%[21]. - The company’s total equity attributable to shareholders decreased by 0.66% to ¥3,705,741,472.18 from ¥3,730,544,275.59 at the end of the previous year[5]. Research and Development - Research and development expenses surged by 117.68% to ¥240,479,825.00 in Q1 2025, up from ¥110,476,228.75 in Q1 2024, due to multiple products being in clinical development[11]. - Research and development expenses surged to ¥240,479,825.00, representing a significant increase from ¥110,476,228.75 in the previous period[22]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 11,564[14]. - The largest shareholder, Shijiazhuang Yiling Pharmaceutical Co., Ltd., holds 73.77% of shares, totaling 1,036,159,894 shares[14]. - The company has 157,520,510 restricted shares held by Shijiazhuang Yiling Pharmaceutical Co., Ltd., which are subject to a 36-month transfer restriction[16]. - The total number of shares held by the top 10 unrestricted shareholders is 878,639,384 shares[14]. - The company has not disclosed any changes in the top 10 shareholders due to margin trading activities[15]. - The company has not reported any changes in the number of preferred shareholders or their holdings[15]. - The company’s stock structure includes various institutional investors, with the top 10 shareholders holding a significant portion of the shares[14]. - The company’s financial disclosures indicate a commitment to transparency regarding shareholder relationships and potential risks associated with stock transfers[17]. Acquisition Plans - The company plans to acquire 100% equity of Shijiazhuang Baike Biopharmaceutical Co., Ltd. through a combination of cash and stock issuance, with the transaction currently under review by the Shenzhen Stock Exchange[17]. - The company will continue to provide updates on the acquisition process as it progresses through regulatory reviews[17].